A Phase 1 first-in-human DLK1-directed immunotherapy clinical trial to treat neuroendocrine neoplasms, including neuroblastoma, in adult patients is currently open (ClinicalTrials.gov: NCT06041516). This evidence concerns the gene DLK1 and neuroendocrine neoplasm.